| Amy Louise Pinkerton, SLP | |
|
1375 S Columbia Rd - Altru Performance Center, Grand Forks, ND 58201 | |
| (701) 780-5000 | |
| (701) 780-2238 |
| Full Name | Amy Louise Pinkerton |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 8 Years |
| Location | 1375 S Columbia Rd - Altru Performance Center, Grand Forks, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053854968 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1528 (North Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State University Of Iowa | 7618884230 | 1476 |
News Archive
One of the major side effects of chemotherapy is a sharp drop in white blood cells, which leaves patients vulnerable to dangerous infections. MIT researchers have now developed a portable device that could be used to monitor patients' white blood cell levels at home, without taking blood samples.
Engineered strands of DNA - nanoscale tools called "nanoswitches" - could be the key to faster, easier, cheaper and more sensitive tests that can enable high-fidelity detection of biomarkers indicating the presence of different diseases, viral strains and even genetic variabilities as subtle as a single-gene mutation.
Researchers have developed a statistical model for projecting how many people will get sick from seasonal influenza based on analyses of flu viruses circulating that season. The research, conducted by scientists at the National Institutes of Health, appears today in the open-access publication PLoS Currents: Influenza.
People who have a greater risk of developing schizophrenia are more likely to try cannabis, according to new research, which also found a causal link between trying the drug and an increased risk of the condition.
Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).
› Verified 6 days ago
| Provider Name | State University Of Iowa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
One of the major side effects of chemotherapy is a sharp drop in white blood cells, which leaves patients vulnerable to dangerous infections. MIT researchers have now developed a portable device that could be used to monitor patients' white blood cell levels at home, without taking blood samples.
Engineered strands of DNA - nanoscale tools called "nanoswitches" - could be the key to faster, easier, cheaper and more sensitive tests that can enable high-fidelity detection of biomarkers indicating the presence of different diseases, viral strains and even genetic variabilities as subtle as a single-gene mutation.
Researchers have developed a statistical model for projecting how many people will get sick from seasonal influenza based on analyses of flu viruses circulating that season. The research, conducted by scientists at the National Institutes of Health, appears today in the open-access publication PLoS Currents: Influenza.
People who have a greater risk of developing schizophrenia are more likely to try cannabis, according to new research, which also found a causal link between trying the drug and an increased risk of the condition.
Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Louise Pinkerton, SLP 2401 Demers Ave, Grand Forks, ND 58201 Ph: (701) 780-1891 | Amy Louise Pinkerton, SLP 1375 S Columbia Rd - Altru Performance Center, Grand Forks, ND 58201 Ph: (701) 780-5000 |
News Archive
One of the major side effects of chemotherapy is a sharp drop in white blood cells, which leaves patients vulnerable to dangerous infections. MIT researchers have now developed a portable device that could be used to monitor patients' white blood cell levels at home, without taking blood samples.
Engineered strands of DNA - nanoscale tools called "nanoswitches" - could be the key to faster, easier, cheaper and more sensitive tests that can enable high-fidelity detection of biomarkers indicating the presence of different diseases, viral strains and even genetic variabilities as subtle as a single-gene mutation.
Researchers have developed a statistical model for projecting how many people will get sick from seasonal influenza based on analyses of flu viruses circulating that season. The research, conducted by scientists at the National Institutes of Health, appears today in the open-access publication PLoS Currents: Influenza.
People who have a greater risk of developing schizophrenia are more likely to try cannabis, according to new research, which also found a causal link between trying the drug and an increased risk of the condition.
Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).
› Verified 6 days ago
Andrea Fernandez Flores, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2600 Demers Ave Ste 101, Grand Forks, ND 58201 Phone: 701-741-8057 | |
Jessica Ann Sporbert, SPEECH PATHOLOGIST Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2400 47th Ave S, Grand Forks, ND 58201 Phone: 701-746-2230 | |
Meredith A. Christiansen, M.S., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2600 Demers Ave Ste 101, Grand Forks, ND 58201 Phone: 701-741-8057 | |
Paola Alvarez, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2400 47th Ave S, Grand Forks, ND 58201 Phone: 701-746-2205 | |
Andrea Goertzen, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2400 47th Ave S, Grand Forks, ND 58201 Phone: 701-746-2230 | |
Jody Lynn Paulson, M.S. CCC-SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 1000 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-5000 |